Alkem Laboratories Limited has announced the outcome of its Board Meeting held on November 12, 2026. The Board has approved the standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026. These results, along with the limited review report from the Statutory Auditors, have been submitted. The meeting commenced at 11:30 a.m. and concluded at 1:40 p.m. The information is also available on the company’s website.
Board Approves Financial Results
Alkem Laboratories Limited convened its Board Meeting on November 12, 2026, during which the company’s standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026 were approved. This announcement follows a prior intimation regarding the Board Meeting, as per SEBI LODR Regulations.
Key Financial Information Disclosed
The approved financial results, along with the accompanying Limited Review Report from the Statutory Auditors, have been furnished as required. The Board Meeting took place from 11:30 a.m. to 1:40 p.m. on the aforementioned date.
Accessibility of Information
Further details regarding the financial results are accessible on the company’s official website at www.alkemlabs.com.
Independent Auditor’s Review
The consolidated financial results have been reviewed by Deloitte Haskins & Sells LLP, Chartered Accountants. The auditors’ report states that based on their review, nothing has come to their attention that causes them to believe that the accompanying statement, prepared in accordance with Indian Accounting Standards and other generally accepted accounting principles, contains any material misstatement or fails to disclose required information.
The auditor’s report also notes the inclusion of interim financial information for subsidiaries and associates, some of which were reviewed by other auditors and some not reviewed by their auditors. The materiality of these included results has been considered in the conclusion.
Standalone Financial Results Review
Similarly, the standalone financial results of Alkem Laboratories Limited for the quarter and six months ended September 30, 2026 have also undergone a review by Deloitte Haskins & Sells LLP. The auditors have issued an unmodified review report, confirming compliance with accounting standards and SEBI regulations, and finding no material misstatement.
Segmental Information
The report includes detailed segment information for Pharmaceuticals, Biotech, and MedTech. For the six months ended September 30, 2026, Pharmaceuticals segment revenue was ₹80,012.4 million, Biotech was ₹2,496.5 million, and MedTech was ₹1,407.9 million. Total revenue from operations stood at ₹82,921.4 million.
Segment results show Pharmaceuticals with a profit of ₹18,212.7 million, while Biotech reported a loss of ₹2,054.2 million, and MedTech had a loss of ₹618.8 million before interest, unallocable income, and exceptional items. The total profit before tax and exceptional items for the consolidated results was ₹17,366.4 million.
Consolidated Balance Sheet Highlights
As at September 30, 2026, total assets amounted to ₹230,596.4 million. Total equity stood at ₹156,890.0 million, with equity attributable to owners of the Company at ₹148,652.1 million. Non-current liabilities were ₹26,615.5 million, and current liabilities were ₹47,090.9 million.
Consolidated Cash Flow Summary
For the six months ended September 30, 2026, net cash generated from operating activities was ₹10,445.8 million. Investing activities used net cash of ₹3,783.1 million, while financing activities used net cash of ₹4,439.2 million. The net decrease in cash and cash equivalents for the period was ₹2,223.5 million.
Standalone Balance Sheet Details
As at September 30, 2026, standalone total assets were ₹183,095.8 million. Total equity was ₹152,065.4 million. Non-current liabilities amounted to ₹5,591.4 million, and current liabilities totaled ₹25,439.0 million.
Standalone Cash Flow Statement
For the six months ended September 30, 2026, standalone net cash generated from operating activities was ₹9,641.5 million. Investing activities used net cash of ₹4,219.6 million, and financing activities used net cash of ₹4,693.8 million. The net decrease in cash and cash equivalents was ₹1,529.1 million.
Discontinued Operations
Key financial information for discontinued operations is provided, with total income for the six months ended September 30, 2026, at ₹5,622.8 million and net profit after tax at ₹630.7 million.
Source: BSE
